A single institutional retrospective evaluation for younger patients with primary central nervous lymphomas on a modified R-MPV regimen followed by radiotherapy and high dose cytarabine.

摘要: We conducted a retrospective analysis of patients younger than 60 years (N = 10, median age 54.5) with newly diagnosed primary central nervous system lymphoma (PCNSL) at the University Tsukuba Hospital from January 2008 to November 2016. All were scheduled receive single regimen without registration any clinical trials. This was based on phase 2 study by Memorial Sloan-Kettering Cancer Center (MSKCC); induction chemotherapy rituximab, methotrexate, procarbazine, and vincristine (R-MPV) (five seven cycles), followed whole-brain radiotherapy (rd-WBRT) (23.4 Gy) two high-dose cytarabine (HD-AC) cycles as consolidation. The 54.5 years, follow up duration 33.1 months. 3-year overall survival (OS) progression-free (PFS) 69% (95% CI 31-89%) 56% 20-81%). OS PFS not reached, respectively. Acute delayed toxicities manageable. In particular, who achieved CR R-MPV significantly superb (3-year OS, 100%; PFS, 80%), implying that large proportion in after completion this treatment may achieve durable disease control. On other hand, all three had progressive during died progression within 1 year diagnosis achieving CR. Identifying having risk failure is important, allow us consider potentially more effective regimen.